These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39293124)

  • 41. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
    Saidha S; Syc SB; Durbin MK; Eckstein C; Oakley JD; Meyer SA; Conger A; Frohman TC; Newsome S; Ratchford JN; Frohman EM; Calabresi PA
    Mult Scler; 2011 Dec; 17(12):1449-63. PubMed ID: 21865411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
    Pisa M; Ratti F; Vabanesi M; Radaelli M; Guerrieri S; Moiola L; Martinelli V; Comi G; Leocani L
    Mult Scler; 2020 Sep; 26(10):1197-1206. PubMed ID: 31392924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis.
    Behbehani R; Adnan H; Al-Hassan AA; Al-Salahat A; Alroughani R
    Mult Scler Relat Disord; 2018 Apr; 21():56-62. PubMed ID: 29459346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
    Zivadinov R; Tavazzi E; Hagemeier J; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B
    CNS Drugs; 2018 Aug; 32(8):763-770. PubMed ID: 29767815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS.
    Pisa M; Guerrieri S; Di Maggio G; Medaglini S; Moiola L; Martinelli V; Comi G; Leocani L
    Neurology; 2017 Dec; 89(24):2469-2475. PubMed ID: 29142087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis.
    El Ayoubi NK; Sabbagh HM; Bou Rjeily N; Hannoun S; Khoury SJ
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Vavasour IM; Tam R; Li DK; Laule C; Taylor C; Kolind SH; MacKay AL; Javed A; Traboulsee A
    Mult Scler; 2019 May; 25(6):811-818. PubMed ID: 29663845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS.
    Stellmann JP; Cetin H; Young KL; Hodecker S; Pöttgen J; Bittersohl D; Hassenstein A; Oberwahrenbrock T; Heesen C; Siemonsen S
    Brain Behav; 2017 Feb; 7(2):e00614. PubMed ID: 28239524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identifying Optical Coherence Tomography Markers for Multiple Sclerosis Diagnosis and Management.
    Cujba L; Stan C; Samoila O; Drugan T; Benedec Cutas A; Nicula C
    Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    Alcalá C; Gascón F; Pérez-Miralles F; Domínguez JA; Gil-Perotín S; Casanova B
    J Neurol; 2019 Mar; 266(3):726-734. PubMed ID: 30661133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.
    Nygaard GO; Celius EG; de Rodez Benavent SA; Sowa P; Gustavsen MW; Fjell AM; Landrø NI; Walhovd KB; Harbo HF
    PLoS One; 2015; 10(8):e0135974. PubMed ID: 26280173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Sotirchos ES; Vasileiou ES; Filippatou AG; Fitzgerald KC; Smith MD; Lord HN; Kalaitzidis G; Lambe J; Duval A; Prince JL; Mowry EM; Saidha S; Calabresi PA
    Neurology; 2022 Aug; 99(7):e688-e697. PubMed ID: 35618438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
    Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
    CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
    Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
    Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study.
    Dong X; Xu G; Wang J; Yin N; Meng N
    Mult Scler Relat Disord; 2022 Sep; 65():103838. PubMed ID: 35749960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis.
    González-López JJ; Rebolleda G; Leal M; Oblanca N; Muñoz-Negrete FJ; Costa-Frossard L; Alvarez-Cermeño JC
    Biomed Res Int; 2014; 2014():128517. PubMed ID: 25313352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Havrdova E; Arnold DL; Cohen JA; Hartung HP; Fox EJ; Giovannoni G; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Rodriguez CE; Jody D; Hogan RJ; Xenopoulos P; Panzara MA; Coles AJ;
    Neurology; 2017 Sep; 89(11):1107-1116. PubMed ID: 28835401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Coles AJ; Cohen JA; Fox EJ; Giovannoni G; Hartung HP; Havrdova E; Schippling S; Selmaj KW; Traboulsee A; Compston DAS; Margolin DH; Thangavelu K; Chirieac MC; Jody D; Xenopoulos P; Hogan RJ; Panzara MA; Arnold DL;
    Neurology; 2017 Sep; 89(11):1117-1126. PubMed ID: 28835403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.